Frank Mauler
Bayer Health Care
PH-R-EU CNS
Aprather Weg 18a
42096 Wuppertal
Germany
Name/email consistency: high
- Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Mauler, F., Hinz, V., Augstein, K.H., Fassbender, M., Horváth, E. Brain Res. (2003)
- BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. Mauler, F., Horváth, E., De Vry, J., Jäger, R., Schwarz, T., Sandmann, S., Weinz, C., Heinig, R., Böttcher, M. CNS. Drug. Rev (2003)
- Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. Mauler, F., Mittendorf, J., Horváth, E., De Vry, J. J. Pharmacol. Exp. Ther. (2002)
- Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY x 3702 in vitro and in vivo. Mauler, F., Fahrig, T., Horváth, E., Jork, R. Brain Res. (2001)